Sign inJoin waitlistJoin the waitlist

Priyanka Pophali

Internal Medicine Residency · University of Wisconsin Hospitals and Clinics

Credentials: · · · ·

History

Internal Medicine
University of Wisconsin Hospitals and Clinics
2024–Present
Hematology and Medical Oncology
Mayo Clinic
2027–2030
Indira Gandhi Government Medical College, Nagpur
2006–2010

Research

The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Review · The Cancer Journal · 2016 · First of 2 authors · 100 citations
CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML
Bone Marrow Transplantation · 2013 · 83 citations
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
Blood · 2025 · 33 citations

MB
Minocher Battiwalla
9 papers
SI
Sawa Ito
8 papers
AB
Austin Barrett
6 papers
NJ
Natasha Jain
6 papers · 6 as a resident
Reem Karmali
6 papers
Thomas Habermann
6 papers
Brian Hill
5 papers
Carrie Thompson
5 papers
Natalie Grover
5 papers
Ajay Major
4 papers · 1 as a fellow
Alex Niu
4 papers · 2 as a resident
Allison Rosenthal
4 papers

Clinical trials

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Site PI · Recruiting · Phase 3
Eastern Cooperative Oncology Group
2025–2075
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2038
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2023–2030